High Prevalence and Conservative Management of Acute Cholecystitis during Lenvatinib for Advanced Thyroid Cancer

INTRODUCTION: Lenvatinib (LEN) is a multitarget tyrosine kinase inhibitor currently used for advanced, radioiodine refractory differentiated thyroid cancer (RAI-R DTC). Among adverse events (AEs), nausea, vomiting, and decreased appetite have been frequently described. We aimed to evaluate the preva...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Eur Thyroid J
Main Authors: Di Stefano, Marta, Colombo, Carla, De Leo, Simone, Perrino, Michela, Viganò, Mauro, Persani, Luca, Fugazzola, Laura
Format: Artigo
Jezik:Inglês
Izdano: S. Karger AG 2021
Teme:
Clinical Thyroidology / Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8314780/
https://ncbi.nlm.nih.gov/pubmed/34395303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000510369
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki